Cladribine (Mavenclad) Prior Authorization
Customize your policy alerts
Sign up for all mediviewcurative policy alerts
Know when mediviewcurative releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements for cladribine (Mavenclad) for treatment of relapsing forms of multiple sclerosis for members of Curative Health Plan; applies to prescribers requesting coverage.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cladribine (Mavenclad)
Initial Therapy
Covered when ALL of the following are met for initial therapy:
Approval duration: 8 weeks
Continuation Therapy
Covered when ALL of the following are met for continued therapy:
Approval duration: 4 weeks if per cycle; 8 weeks if per course; lifetime limit 2 courses (4 cycles)
Coverage is denied when chart documentation indicates any of the following contraindications or exclusionary conditions: active malignancy; active chronic infections (for example, hepatitis or tuberculosis); HIV infection; pregnancy; or breastfeeding while receiving cladribine treatment and for 10 days after the last dose. These conditions must be absent on the relevant chart notes for both initial and continued therapy requests.
For continued therapy, the policy also requires a recent complete differential CBC demonstrating a lymphocyte count meeting the continuation threshold; presence of any of the listed exclusions in follow-up notes is a reason to withhold continued authorization.
Requests are not medically necessary and will be denied when they exceed the policy’s lifetime treatment limit of 2 courses (4 cycles) or when required evidence of disease activity or prior treatment failure is missing. For initial approvals, the member must have documentation of high disease activity (≥2 relapses in the prior year and ≥1 gadolinium‑enhancing lesion on MRI or significant increase in T2 lesion load) and failure of an adequate trial of at least 2 unique classes of disease‑modifying therapy.
Continued therapy requests must include documentation of clinical benefit and meet safety and timing requirements; absence of documented benefit, missing CBC/lymphocyte data, failure to meet cycle timing, or lack of neurologist involvement are all grounds for denial.
Initial Therapy Requirements
Initial Therapy Requirements
Continued Therapy Requirements
Continued Therapy Requirements
Key Definitions
Drug Coding and Related Clinical Values
| NDC | Cladribine (Mavenclad) product identifier (NDC not specified in document) |
Provider Actions, Documentation, and Denial Triggers
Prior authorization required for cladribine
Prior authorization is required for cladribine (Mavenclad) when used for FDA‑approved indications and the request must meet the policy's initial or continued therapy criteria.
- Approval duration for initial requests: 8 weeks
- Approval duration for continued therapy: 4 weeks per cycle or 8 weeks per course
Failure of ≥2 unique DMT classes required
Document that the patient has failed an adequate trial of at least two unique classes of disease‑modifying therapy prior to approval of cladribine.
- Examples of DMT classes listed include monoclonal antibodies (ocrelizumab, rituximab, natalizumab), fingolimod, teriflunomide, dimethyl fumarate, glatiramer/Glatopa, and interferons (Betaseron, Plegridy).
Required chart notes and labs for prior authorization
Include recent chart documentation and labs: for initial requests, chart notes within the past 120 days; for continuation requests, chart notes within the past 12 months and evidence of clinical benefit.
- Diagnosis of relapsing MS (RRMS or SPMS) and ambulatory status if SPMS
- Relapse history and MRI findings demonstrating highly active disease (≥2 relapses in prior year and ≥1 gadolinium‑enhancing lesion or significant increase in T2 lesion load) for initial therapy
- Documentation of prior DMT trials and inadequate response
- Differential CBC with lymphocyte count (within normal limits for initial; ≥800 cells/µL for continued therapy)
- Prescriber is or consulted with a neurologist
Common triggers for denial
Requests are likely to be denied if the submission lacks required diagnosis, evidence of high disease activity, prior DMT failures, or shows exclusionary conditions or exceeded lifetime limits.
- No documentation of relapsing multiple sclerosis (RRMS or SPMS) or ambulatory status when SPMS
- Missing evidence of high disease activity (not ≥2 relapses in prior year and/or no MRI activity as specified)
- No documentation of failure of at least two unique DMT classes
- Presence of exclusionary conditions: active malignancy, active chronic infections (e.g., hepatitis or tuberculosis), HIV infection, pregnancy, or breastfeeding during treatment and for 10 days after last dose
- Request exceeds lifetime limit of 2 courses (4 cycles)
Step Therapy Requirements
| Step | Requirement | Documentation / Notes |
|---|---|---|
| {"text":"1","status":""},{"text":"Must document prior use and inadequate response (failed an adequate trial) to at least 2 unique classes of disease-modifying therapy","status":""},{"text":"Provide chart documentation of prior DMT trials (examples: monoclonal antibodies such as ocrelizumab, rituximab, natalizumab; fingolimod; teriflunomide; dimethyl fumarate; glatiramer/Glatopa; interferons) within the medical record","status":""} |
Background
Cladribine (Mavenclad) is an oral disease‑modifying therapy for treatment of relapsing forms of multiple sclerosis (relapsing‑remitting MS and secondary progressive MS with relapse history). The policy applies to patients with highly active disease or those who have had inadequate response to prior therapies and distinguishes between initial and continued therapy requirements, including pre‑treatment safety screening (CBC with lymphocyte count), neurologist involvement, and lifetime limits on treatment courses and cycles.
Initial authorization is granted only when all criteria are met (including diagnosis, high disease activity, failure of ≥2 unique DMT classes, normal baseline lymphocyte count, absence of exclusions, and prescriber/consultation by a neurologist); initial approval duration is 8 weeks. Continued therapy requires documented clinical benefit, a lymphocyte count of at least 800 cells/microliter, adherence to cycle timing rules, ongoing absence of exclusions, and respects the lifetime limit of 2 courses (4 cycles).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.